Respiratory syncytial virus (RSV) immunisation
Up to date recommendations, vaccine schedules and resources on RSV (Respiratory syncytial virus) for immunisation providers.
www.health.vic.gov.auHere’s the latest on RSV vaccines in Australia as of now.
-
Arexvy approved for adults 60 and older: Australia’s Therapeutic Goods Administration (TGA) approved Arexvy for Australians aged 60+, marking the first RSV vaccine approved in the country for this age group. Availability has been rolled out primarily through private channels, with supply and pricing details expected from health authorities soon after approval. This milestone followed U.S. approval and aligns with Australia’s interest in protecting older adults from severe RSV outcomes. [Source: Guardian article on TGA approval for Arexvy in Australia ][1]
-
Abrysvo and other RSV interventions: Australia’s immunisation framework includes Abrysvo (another RSV vaccine) and Beyfortus (nirsevimab) for infants and certain at-risk groups, with guidance published by state/territory health authorities and the Australian Immunisation Handbook. This reflects a broader strategy to protect both pregnant women and young children, alongside older adults. [Source: Health Victoria and Monash/other health resources summarizing RSV vaccine approvals and scheduling ][3][5]
-
Access in practice during 2024–2025: In 2024, RSV vaccines became available in the private market for eligible older adults, and state programs began offering monoclonal antibodies to infants in some jurisdictions. News coverage highlighted that access could vary by state and funding availability, with ongoing discussions about making vaccines more widely free or subsidised for high-risk groups. [Source: ABC News Australia coverage of vaccine availability for winter 2024, 9 News coverage on funding considerations ][7][3]
-
What to expect going forward: Australian health authorities have indicated further RSV vaccine approvals and program expansions (including maternal vaccination with Abrysvo in pregnancy) as the NIP evolves, with updates on supply, pricing, and eligibility expected from federal and state health departments. [Source: SEMPHN RSV resources and Victorian health page detailing current immunisation products and schedules ][4][5]
If you’d like, I can:
- Narrow to a specific state or city in Australia and summarize any local access issues or vaccination programs.
- Look up the latest official TGA or Australian Department of Health statements for precise eligibility and pricing details.
- Pull a quick one-page brief with a timeline of RSV vaccine approvals in Australia and key upcoming milestones.